

Ryan Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2095399/publications.pdf>

Version: 2024-02-01

44
papers

1,314
citations

304743

22
h-index

377865

34
g-index

46
all docs

46
docs citations

46
times ranked

1354
citing authors

#	ARTICLE	IF	CITATIONS
1	Increasing the structural coverage of tuberculosis drug targets. <i>Tuberculosis</i> , 2015, 95, 142-148.	1.9	103
2	A Specific Inhibitor of PfCDPK4 Blocks Malaria Transmission: Chemical-genetic Validation. <i>Journal of Infectious Diseases</i> , 2014, 209, 275-284.	4.0	83
3	Development of an Orally Available and Central Nervous System (CNS) Penetrant <i>Toxoplasma gondii</i> Calcium-Dependent Protein Kinase 1 (CDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of <i>Toxoplasmosis</i> . <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6531-6546.	6.4	81
4	Immobilized metal-affinity chromatography protein-recovery screening is predictive of crystallographic structure success. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2011, 67, 998-1005.	0.7	79
5	Extended-spectrum antiprotozoal bumped kinase inhibitors: A review. <i>Experimental Parasitology</i> , 2017, 180, 71-83.	1.2	71
6	Development of potent and selective <i>Plasmodium falciparum</i> calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes. <i>European Journal of Medicinal Chemistry</i> , 2014, 74, 562-573.	5.5	54
7	Development of a murine vertical transmission model for <i>Toxoplasma gondii</i> oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2334-2341.	3.0	52
8	Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 1275-1284.	4.0	52
9	Potent and Selective Inhibitors of CDPK1 from <i>T. gondii</i> and <i>C. parvum</i> Based on a 5-Aminopyrazole-4-carboxamide Scaffold. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 40-44.	2.8	49
10	The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites. <i>Parasitology</i> , 2014, 141, 1499-1509.	1.5	47
11	Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the <i>Plasmodium falciparum</i> Drug Target, Prolyl-tRNA-synthetase. <i>ACS Infectious Diseases</i> , 2017, 3, 34-44.	3.8	45
12	Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating <i>Cryptosporidium</i> Infection. <i>Journal of Infectious Diseases</i> , 2017, 216, 55-63.	4.0	44
13	Screening of the Pathogen Box for inhibitors with dual efficacy against <i>Giardia lamblia</i> and <i>Cryptosporidium parvum</i> . <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006673.	3.0	37
14	Optimization of Methionyl tRNA-Synthetase Inhibitors for Treatment of <i>Cryptosporidium</i> Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	37
15	Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned. <i>International Journal for Parasitology</i> , 2020, 50, 413-422.	3.1	37
16	SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of <i>Toxoplasma gondii</i> CDPK1. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1184-1189.	2.8	32
17	Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by <i>Cryptosporidium hominis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	31
18	Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. <i>International Journal for Parasitology</i> , 2017, 47, 753-763.	3.1	30

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of the bumped kinase inhibitor BKI-1553 in pregnant sheep experimentally infected with <i>Neospora caninum</i> tachyzoites. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2018, 8, 112-124.	3.4	28
20	Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3135-3146.	6.4	27
21	High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity. <i>PLoS ONE</i> , 2021, 16, e0250019.	2.5	27
22	Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with <i>Toxoplasma gondii</i> during Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	23
23	Selective inhibition of <i>Sarcocystis neurona</i> calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy. <i>International Journal for Parasitology</i> , 2016, 46, 871-880.	3.1	22
24	<i>Brucella melitensis</i> Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis. <i>PLoS ONE</i> , 2016, 11, e0160350.	2.5	21
25	Bumped kinase inhibitor prohibits egression in <i>Babesia bovis</i> . <i>Veterinary Parasitology</i> , 2016, 215, 22-28.	1.8	19
26	5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of <i>Cryptosporidium parvum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	17
27	In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with <i>Neospora caninum</i> tachyzoites and <i>Toxoplasma gondii</i> oocysts. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2021, 16, 90-101.	3.4	17
28	One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases. <i>Veterinary Parasitology</i> , 2021, 289, 109336.	1.8	16
29	5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of <i>Plasmodium falciparum</i> microgametocyte eflagellation and potential malaria transmission blocking agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5487-5491.	2.2	15
30	Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis. <i>Journal of Infectious Diseases</i> , 2019, 219, 1464-1473.	4.0	13
31	<i>Toxoplasma</i> Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	12
32	Bumped kinase inhibitor 1369 is effective against <i>Cystoisospora suis</i> in vivo and in vitro. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 10, 9-19.	3.4	12
33	Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106099.	2.5	12
34	Structures of glyceraldehyde 3-phosphate dehydrogenase in <i>Neisseria gonorrhoeae</i> and <i>Chlamydia trachomatis</i> . <i>Protein Science</i> , 2020, 29, 768-778.	7.6	10
35	Evaluation of in vitro and in vivo antibiotic efficacy against a novel bioluminescent <i>Shigella flexneri</i> . <i>Scientific Reports</i> , 2019, 9, 13567.	3.3	8
36	Repurposing Infectious Disease Hits as Anti- <i>Cryptosporidium</i> Leads. <i>ACS Infectious Diseases</i> , 2021, 7, 1275-1282.	3.8	8

#	ARTICLE	IF	CITATIONS
37	P-Glycoprotein-Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite <i>Cryptosporidium</i> . <i>Journal of Infectious Diseases</i> , 2019, 220, 1188-1198.	4.0	7
38	Endochin-like quinolones (ELQs) and bumped kinase inhibitors (BKIs): Synergistic and additive effects of combined treatments against <i>Neospora caninum</i> infection in vitro and in vivo. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2021, 17, 92-106.	3.4	7
39	Taming the Boys for Global Good: Contraceptive Strategy to Stop Malaria Transmission. <i>Molecules</i> , 2020, 25, 2773.	3.8	6
40	7H-Pyrrolo[2,3-d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1H-Pyrazolo[3,4-d]pyrimidin-4-amine-Based Inhibitors. <i>ACS Infectious Diseases</i> , 2018, 4, 516-522.	3.8	5
41	A short-term treatment with BKI-1294 does not protect foetuses from sheep experimentally infected with <i>Neospora caninum</i> tachyzoites during pregnancy. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2021, 17, 176-185.	3.4	5
42	Reduced treatment frequencies with bumped kinase inhibitor 1369 are effective against porcine cystoisosporosis. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2020, 14, 37-45.	3.4	3
43	Pyrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis. <i>ACS Infectious Diseases</i> , 2021, 7, 1200-1207.	3.8	3
44	Repurposing the Kinase Inhibitor Mavelertinib for Giardiasis Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.2	3